3 thoughts on “Enter The Death Panels”

  1. wow…seems like there is a lot of information missing from this piece. This drug was given “accelerated” approved by the FDA in 2008 (even though the FDA advisory panel voted against the approval) which came with conditions, including new clinical testing. Those clinical trials have since been performed and have shown little evidence that breast cancer patients benefit from Avastin and that the risks outweigh the benefits. So the advisory panel is recommending the approval for this drug to be used on breast cancer patients be removed (but are fine with it continuing to be used as treatment for colon, lung, brain and kidney cancers); however, there is no requirement for the FDA to agree with the advisory panel or act on their recommendation.
    I agree with Ace’s opening statement… “The FDA is not supposed to consider costs of treatment. Their mandate is to determine if a drug is “safe and effective,” period.”…it appears that is exactly what they have done in this instance.
    I guess labeling this as a favor to Obama or including the words death panel probably gets more hits on a website than a non-sensational posting about an advisory recommendation.

  2. cse,
    Please discontinue using any sort of factual information here. It is much easier to call Obama a bad guy, a socialist and a death panel dude and promote the virtues of Sarah Palin. Crank does elaborate research sometimes but he often puts his foot in it and this would appear to be one of those times.

  3. Yes, those damn facts get in the way of political hyperbole, particularly someone as unhinged as “Ace.”
    Advisory Panel Votes 12-1 to Reverse Avastin’s Approval as a Breast Cancer Drug
    By Daniel J. DeNoon
    WebMD Health News
    Reviewed by Laura J. Martin, MDJuly 20, 2010 —
    Avastin is not helpful in the treatment of metastatic breast cancer, and the drug’s approval for this use should be withdrawn.
    That’s the verdict of an FDA advisory panel, whose 12-1 vote urges the FDA to remove breast cancer from the list of approved uses of the Genentech drug. The vote is specific to breast cancer and does not affect Avastin’s approval for the treatment of colon, lung, brain, or kidney cancer.
    Against the advice of a previous advisory committee, the FDA in 2008 gave Avastin “accelerated approval” for the treatment of spreading breast cancer, in combination with chemotherapy. As a condition of that approval, Genentech agreed to conduct two new clinical trials.
    Those trials showed no evidence that Avastin offered an overall benefit to breast cancer patients. In contrast, the drug added significantly to the side effects of chemotherapy.
    Avastin is a man-made antibody that blocks the chemical signals that tumors use to grow new blood vessels. By preventing the growth of new blood vessels, the drug starves tumors.
    But clinical trials showed little evidence that breast cancer patients benefit by adding Avastin to chemotherapy. The drug increased the rate at which these patients experienced serious side effects.
    Briefing documents prepared for the panel by FDA staff painted a dim picture, suggesting Avastin’s risks outweigh its benefits.
    But Genentech noted that Avastin did not shorten patient survival, and that the drug should be tried in more patients with metastatic breast cancer in order to find out how it might best be used. Far from withdrawing its earlier approval, Genentech argued, the FDA should grant Avastin full approval for a wider group of patients.
    The FDA is not bound by the decisions of its advisory panels, which are made up of experts drawn from outside the FDA. However, it’s rare for the federal agency to buck a panel’s near-unanimous decision.

Comments are closed.